Navigation Links
Interim Data Announced for BIBF 1120 as Compared to bevacizumab in Combination Chemotherapy in Metastatic Colorectal Cancer
Date:9/27/2011

an estimated 49,380 related deaths are expected to occur in 2011, which will account for about 9 percent of all cancer deaths.(5)

About Boehringer Ingelheim in Oncology

Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research program to develop innovative cancer drugs. Working in close collaboration with the international scientific community and a number of the world's leading cancer centers, Boehringer Ingelheim is committed to discovering and developing novel cancer treatments. This commitment is underpinned by using advances in science to develop a range of targeted therapies in areas of medical need, including seven investigational compounds in different phases of development for solid tumors and hematological cancers.

The current focus of research includes compounds in three areas: angiogenesis inhibition, signal transduction inhibition and cell-cycle kinase inhibition.  Afatinib is currently in phase III clinical development in NSCLC and breast cancer.  Apart from afatinib, Boehringer Ingelheim's late-stage oncology portfolio includes BIBF 1120, an investigational orally-administered triple angiokinase inhibitor that targets three of the receptor tyrosine kinases shown to aid in the regulation of angiogenesis (formation of blood vessels): fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR).  As angiogenesis plays a pivotal role in the growth of all solid tumors, (6,7) BIBF 1120 is currently being investigated in a number of cancers including NSCLC, ovarian, hepatocellular and colorectal cancers.  BIBF 1120 and afatinib are not approved by the FDA; their safety and efficacy have not been established.  

In the area of cell-cycle kinase inhibition, Boehrin
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
11. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...  ViewRay™, a privately held medical device company, announced today ... with ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) to ... of cancer in Japan . ViewRay,s ... and only MRI-guided radiation therapy system that images and ...
(Date:1/22/2015)... Inc. (NASDAQ: UPI ), a medical device company ... treat voiding dysfunctions, today reported financial results for the ... Global revenue for the Company,s Urgent ®  PC Neuromodulation ... revenue record, as compared to $3.9 million in the ...
(Date:1/22/2015)... /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), ... for cardiovascular disease and overall health is pleased to provide ... and its outlook for 2015 from the CEO, Mr. ... We would like to take this opportunity to share with ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... Fla. , July 6 Biotechnology pioneer Divine Skin ... consumer health-care division to capitalize on the pharmaceutical research it has ... skin. The new division will target both over-the-counter and prescription drug ... In ...
... Reportlinker.com announces that a new market research report is available in its ... European Markets for Gastrointestinal Endoscopic ... , http://www.reportlinker.com/p0196554/European-Markets-for-Gastrointestinal-Endoscopic-Devices-2010-15-Countries.html ... The European market for gastrointestinal endoscopic ...
Cached Medicine Technology:Divine Skin (DSKX) Launches Health-Care Division To Develop New OTC and Prescription Drugs 2Divine Skin (DSKX) Launches Health-Care Division To Develop New OTC and Prescription Drugs 3Divine Skin (DSKX) Launches Health-Care Division To Develop New OTC and Prescription Drugs 4Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 2Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 3Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 4Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 5Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 6Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 7Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 8Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 9Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 10Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 11Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 12Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 13Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 14Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 15Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 16Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 17Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 18Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 19Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 20Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 21Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 22Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 23Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 24Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 25Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 26Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 27Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 28Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 29Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 30Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 31Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 32Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 33
(Date:1/22/2015)... 2015 Liberty University has received accreditation for ... from the Council for Accreditation of Counseling & Related ... Center for Counseling & Family Studies , is under ... university’s new School of Behavioral Sciences. Prior to the formation ...
(Date:1/22/2015)... Chemo Duck Program is pleased to announce the release of the ... with cancer. The Chemo Duck App, available on iTunes for use ... to help children of all ages living with cancer adjust to ... entertained, educated and at ease while waiting for clinic visits or ...
(Date:1/22/2015)... is a famous wedding dress company offering many trendy designs. ... Facebook, Twitter, and Pinterest. The fans will have an opportunity ... every week. , Moreover, the company has extended its 2015 ... homepage for more information. , Angelweddingdress is a ...
(Date:1/22/2015)... Florida (PRWEB) January 22, 2015 Juvent ... today at the 2015 PGA Merchandise Show to bestow ... and incredible female amateur golfer, Arlene McKitrick. The award ... female amateur golf tournament win. She won her first ...
(Date:1/22/2015)... 2015 For over 20 years, Dr. David Cruz ... Vista area has treated just about every type of injury ... And for those same twenty-plus years, the team at ... injuries with the best possible doctor. With the combined ...
Breaking Medicine News(10 mins):Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
... boosted physical, mental scores, study finds , , FRIDAY, March ... poor families boosts children,s physical and mental development, a ... of California, Berkeley found that children in low-income families ... from a government-run conditional cash transfer program were taller, ...
... NEW YORK, March 7 Four out of ... dietary supplement every day, according to the,Institute of ... errors are made due to handwritten prescriptions. These ... drug interactions and,allergic reactions., See video ...
... teaching at ... the Medical Center, COLUMBUS, Ohio, March 7 ... last six years accounting,for nearly 50 percent of the region,s net employment ... jobs, says an economic,impact report released today by the Columbus Chamber of ...
... could enable doctors to rule out tuberculosis (TB) infection ... study published this week in the journal Annals of ... College London and the University of Oxford, shows that ... tuberculosis with 99% accuracy when using the new blood ...
... Dr. Lin Mei, chief of developmental neurobiology at the ... Scholar in Neuroscience, has received the 2008 Mathilde Solowey ... administered by Foundation for Advanced Education in the Sciences, ... that is cutting edge, translational and of broad importance. ...
... wont run into grandparents at your local tanning salon? ... a recent health survey of American adults suggests that while ... many as 10 percent of those between 50 and 64 ... 65 tanned indoors. , Researchers at Fox Chase Cancer Center ...
Cached Medicine News:Health News:Government Assistance Linked to Better Child Development 2Health News:Chamber Analysis Shows OSU Medical Center Leads Area Job Growth 2Health News:Chamber Analysis Shows OSU Medical Center Leads Area Job Growth 3Health News:New TB test means quicker and easier diagnosis for patients 2Health News:New TB test means quicker and easier diagnosis for patients 3Health News:Dr. Mei receives 2008 Mathilde Solowey Lecture Award in Neurosciences 2Health News:Dr. Mei receives 2008 Mathilde Solowey Lecture Award in Neurosciences 3Health News:Teenage girls aren't the only ones who tan indoors -- older adults do so as well 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: